Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Grace Therapeutics, Inc. (GRCE) had Return on Tangible Equity of -14.82% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-2.31M |
|
-- |
|
-- |
|
$2.45M |
|
$-2.45M |
|
$0.13M |
|
$-2.31M |
|
$-2.31M |
|
$-2.31M |
|
$-2.31M |
|
$-2.31M |
|
$-2.31M |
|
$-2.45M |
|
$-2.45M |
|
16.93M |
|
16.93M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$19.21M |
|
$0.01M |
|
$49.28M |
|
$68.49M |
|
$1.28M |
|
-- |
|
$2.31M |
|
$3.60M |
|
$64.89M |
|
$15.63M |
|
$64.89M |
|
15.47M |
|
| Cash Flow Statement Financials | |
$-7.17M |
|
-- |
|
$3.71M |
|
$22.13M |
|
$18.67M |
|
$-3.46M |
|
$0.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.57% |
|
|
Return on Tangible Equity |
-14.82% |
-3.38% |
|
-3.57% |
|
$4.19 |
|
$-0.42 |
|
$-0.42 |
|